Two Doses of BNT162b2 Vaccine Protect Against MIS-C
Two doses of Pfizer-BioNTech vaccine have estimated effectiveness of 91 percent against MIS-C in children aged 12 to 18 years
Miscellaneous Gastrohepatic Disorders
Factors ID’d for Severe GI Effects of SARS-CoV-2 in Children
Among children infected with SARS-CoV-2, 9.5 percent have severe GI effects, such as disseminated adenomesenteritis, appendicitis, pancreatitis
Benralizumab Gets Orphan Drug, Fast Track Designations for 2 Rare GI Diseases
These rare, chronic relapsing conditions are primarily associated with eosinophilic tissue inflammation.
Oral Prodrug of Testosterone Fast Tracked for Nonalcoholic Steatohepatitis
LPCN 1144 treatment was associated with a statistically significant reduction in liver fat compared with placebo.
Lanifibranor Reduces Disease Activity in Nonalcoholic Steatohepatitis
In phase 2b trial, more patients with active NASH had reduction in disease activity score with lanifibranor versus placebo
ACG Updates Clinical Guidelines for Benign Anorectal Disorders
Anorectal biofeedback therapy recommended in defecation disorders; biofeedback also recommended in proctalgia syndrome
Efruxifermin Fast Tracked for Nonalcoholic Steatohepatitis
Efruxifermin is a differentiated Fc-FGF21 fusion protein designed to mimic the biological activity of fibroblast growth factor 21.
Pharmacotherapies for Liver Fibrosis, NASH Resolution Ranked
Although NASH is a common cause of chronic liver disease, there is limited evidence surrounding its management.
Rifaximin Prevents Overt Hepatic Encephalopathy After TIPS
For patients with cirrhosis, rifaximin reduces odds of overt HE after transjugular intrahepatic portosystemic shunt
Gimoti Nasal Spray Now Available for Diabetic Gastroparesis
Gimoti, a dopamine-2 (D2) antagonist, is a nasal spray formulation of metoclopramide.
